Statistical methods in oncology trials
The methods these trials rely on most, based on the statistical analyses posted to ClinicalTrials.gov, with the tutorial that explains each one.
Kaplan-Meier estimation
Time-to-event endpoints
Hazard ratio
Log-rank test
Cochran-Mantel-Haenszel test
Odds ratio
Cox proportional-hazards model
Fisher exact test
All oncology trials
232 results
- MAGNITUDEIndependent statistical analysis of the phase 3 MAGNITUDE trial of niraparib in combination with abiraterone acetate and prednisone versus abiraterone acetate and prednisone in castration-resistant prostate cancer, including rPFS, hazard ratios, confidence…
- MARIPOSAAn independent statistical analysis of the MARIPOSA phase 3 trial of amivantamab plus lazertinib versus osimertinib in locally advanced or metastatic non-small cell lung cancer, including trial design, progression-free survival methodology, results,…
- METEORIndependent statistical analysis of the METEOR phase 3 trial of cabozantinib versus everolimus in metastatic renal cell carcinoma, including progression-free survival, overall survival, objective response rate, trial design, and statistical methodology.
- MIRASOLIndependent statistical analysis of the MIRASOL phase 3 trial of mirvetuximab soravtansine versus investigator's choice chemotherapy in platinum-resistant advanced ovarian, primary peritoneal, or fallopian tube cancers with high FRα expression.
- ML18147Independent statistical analysis of ML18147, a randomized phase 3 trial of bevacizumab plus chemotherapy in metastatic colorectal cancer, including overall survival, progression-free survival, response rate, statistical methodology, safety, and interpretation.
- MONALEESA-2Complete statistical analysis of MONALEESA-2, the randomized phase 3 trial of ribociclib plus letrozole versus placebo plus letrozole in postmenopausal women with advanced or metastatic breast cancer.
- MONALEESA-3Independent statistical analysis of MONALEESA-3 (NCT02422615), a randomized phase 3 trial of ribociclib plus fulvestrant versus placebo plus fulvestrant in advanced breast cancer.
- MONALEESA-7Independent statistical analysis of MONALEESA-7, a randomized phase 3 trial of ribociclib plus endocrine therapy and goserelin versus placebo plus endocrine therapy and goserelin in premenopausal women with hormone receptor-positive, HER2-negative advanced…
- MONARCH 2Independent statistical analysis of the MONARCH 2 phase 3 trial of abemaciclib plus fulvestrant versus placebo plus fulvestrant, including trial design, progression-free survival, statistical methodology, interpretation, limitations, and safety.
- MONARCH 3Independent statistical analysis of the phase 3 MONARCH 3 trial of abemaciclib plus a nonsteroidal aromatase inhibitor in postmenopausal women with breast cancer, including progression-free survival, response, health-status outcomes, methodology, safety, and…
- MONARCH EIndependent statistical analysis of MONARCH E, the randomized phase 3 trial of abemaciclib plus standard adjuvant endocrine therapy versus endocrine therapy in breast cancer, including invasive disease-free survival, distant relapse-free survival, trial…
- NALAIndependent statistical analysis of NALA, a randomized phase 3 trial of neratinib plus capecitabine versus lapatinib plus capecitabine in HER2+ metastatic breast cancer after two or more prior HER2-directed regimens.
- NeoALTTOIndependent statistical analysis of the phase 3 NeoALTTO trial of lapatinib and trastuzumab in neoplasms of the breast, including pathological complete response, event-free survival, overall survival, landmark analyses, methodology, and interpretation.
- NIAGARAIndependent statistical analysis of the phase 3 NIAGARA trial of durvalumab plus gemcitabine/cisplatin in muscle invasive bladder cancer, covering pathologic complete response, event-free survival, secondary endpoints, methodology, and interpretation.
- NO16968Independent statistical analysis of NO16968 (NCT00069121), a randomized phase 3 trial of capecitabine plus oxaliplatin versus 5-FU/LV in colorectal cancer, including disease-free survival, relapse-free survival, overall survival, statistical methodology, and interpretation.
- OCEANSIndependent statistical analysis of the OCEANS phase 3 trial of carboplatin and gemcitabine plus bevacizumab versus placebo in patients with ovary, peritoneal, or fallopian tube carcinoma, including PFS, objective response, overall survival,…
- OlympiAComplete statistical analysis of the OlympiA phase 3 trial of adjuvant olaparib versus placebo in patients with germline BRCA-mutated high-risk HER2-negative primary breast cancer, including trial design, time-to-event endpoints, statistical methods, reported…
- OlympiADIndependent statistical analysis of the OlympiAD phase 3 trial of olaparib monotherapy versus physician's choice chemotherapy in metastatic breast cancer patients with germline BRCA1/2 mutations.
- OPUSIndependent statistical analysis of the OPUS trial of cetuximab plus FOLFOX-4 versus FOLFOX-4 alone as first-line treatment for metastatic colorectal cancer, including response, progression-free survival, overall survival, KRAS subgroup analyses, methodology, and…
- PACIFICComplete statistical analysis of the PACIFIC phase 3 trial of MEDI4736 following concurrent chemoradiation in patients with stage III unresectable non-small cell lung cancer, including primary endpoints, time-to-event methods, secondary analyses, safety,…
- PALLASIndependent statistical analysis of PALLAS (NCT02513394), a randomized phase 3 trial of palbociclib plus standard adjuvant endocrine therapy versus endocrine therapy alone in HR+/HER2- invasive early breast cancer.
- PALOMA-2Independent statistical analysis of PALOMA-2 (NCT01740427), a randomized phase 3 trial of palbociclib plus letrozole versus placebo plus letrozole in postmenopausal women with ER+/HER2- advanced breast cancer.
- PALOMA-3Independent statistical analysis of PALOMA-3, a randomized phase 3 study comparing lazertinib with subcutaneous amivantamab SC-CF versus intravenous amivantamab in participants with EGFR-mutated advanced or metastatic non-small cell lung cancer.
- PALOMA-4Independent statistical analysis of PALOMA-4, a randomized phase 3 trial comparing palbociclib plus letrozole with placebo plus letrozole in Asian postmenopausal women with ER+/HER2- advanced breast cancer.
- PAPILLONIndependent statistical analysis of the phase 3 PAPILLON trial of amivantamab plus chemotherapy versus chemotherapy alone in advanced or metastatic non-small cell lung cancer characterized by EGFR exon 20 insertions.
- PEARLSIndependent statistical analysis of the PEARLS phase 3 trial of pembrolizumab versus placebo after resection in non-small cell lung cancer, including disease-free survival, Cox regression, hazard ratios, confidence intervals, one-sided testing, and…
- POSEIDONIndependent statistical analysis of the phase 3 POSEIDON trial of durvalumab plus tremelimumab with chemotherapy, durvalumab with chemotherapy, or chemotherapy alone in non-small cell lung cancer, including survival, response, methodology, and interpretation.
- PRESERVE 1Independent statistical analysis of PRESERVE 1, a randomized phase 3 trial of trilaciclib versus placebo with FOLFOXIRI/bevacizumab in metastatic colorectal cancer, including primary endpoint results, ANCOVA, Poisson regression, and statistical interpretation.
- PREVAILIndependent statistical analysis of the phase 3 PREVAIL trial of enzalutamide versus placebo in chemotherapy-naive patients with progressive metastatic prostate cancer, including time-to-event endpoints, response analyses, safety, and statistical interpretation.
- PROCLAIMIndependent statistical analysis of the PROCLAIM phase 3 trial, including its randomized design, overall survival analysis, progression-free survival, response, relapse patterns, swallowing outcomes, safety, statistical methods, and interpretation.
- PROFILE 1014Independent statistical analysis of PROFILE 1014, evaluating crizotinib versus pemetrexed plus cisplatin or carboplatin in ALK-positive non-squamous lung cancer, with detailed interpretation of progression-free survival, overall survival, response, patient-reported outcomes, and statistical…
- PROfoundIndependent statistical analysis of the PROfound phase 3 trial of olaparib versus investigators' choice of enzalutamide or abiraterone acetate in men with metastatic castration-resistant prostate cancer, including trial design, time-to-event and response…
- PROpelIndependent statistical analysis of the PROpel phase 3 trial of olaparib plus abiraterone in men with metastatic castration-resistant prostate cancer, including randomized trial design, radiological progression-free survival, overall survival, secondary time-to-event endpoints,…
- PROSPERIndependent statistical analysis of the phase 3 PROSPER trial of enzalutamide versus placebo in nonmetastatic castration-resistant prostate cancer, including metastasis-free survival, secondary time-to-event endpoints, PSA response, statistical methodology, and interpretation.
- QUAZAR AML-001Independent statistical analysis of QUAZAR AML-001, a randomized phase 3 trial of oral azacitidine plus best supportive care versus placebo plus best supportive care as maintenance therapy in acute myeloid leukemia in…
- RAINBOWIndependent statistical analysis of the phase 3 RAINBOW trial of ramucirumab plus paclitaxel versus placebo plus paclitaxel in metastatic gastric adenocarcinoma, including survival, response, quality-of-life, safety, and statistical methodology.
- RATIONALE-301Independent statistical analysis of RATIONALE-301, a randomized phase 3 trial of tislelizumab versus sorafenib in participants with unresectable hepatocellular carcinoma, including overall survival, response, progression, quality of life, and the trial's non-inferiority…
- RATIONALE-303Independent statistical analysis of RATIONALE-303, a randomized phase 3 trial comparing tislelizumab with docetaxel in second- or third-line non-small cell lung cancer, including overall survival, response, progression-free survival, quality of life, and…
- REACHIndependent statistical analysis of the phase 3 REACH trial of ramucirumab plus best supportive care versus placebo plus best supportive care as second-line treatment for hepatocellular carcinoma after sorafenib.
- REACH-2Independent statistical analysis of REACH-2, a randomized phase 3 trial of ramucirumab plus best supportive care versus placebo plus best supportive care in hepatocellular carcinoma with elevated baseline alpha-fetoprotein.
- RECOURSEIndependent statistical analysis of the phase 3 RECOURSE trial of TAS-102 versus placebo in patients with metastatic colorectal cancer refractory to standard chemotherapies, including trial design, time-to-event endpoints, hazard ratios, confidence intervals,…
- RELATIVITY-047Independent statistical analysis of RELATIVITY-047, evaluating relatlimab plus nivolumab versus nivolumab alone in participants with advanced melanoma, including trial design, progression-free survival, statistical methodology, interpretation, and limitations.
- RESORCEIndependent statistical analysis of the phase 3 RESORCE trial of regorafenib versus placebo in hepatocellular carcinoma, including overall survival, time to progression, progression-free survival, tumor response, statistical methodology, and interpretation.
- RTOG 0617Independent statistical analysis of RTOG 0617, evaluating radiation therapy dose and cetuximab with chemotherapy in newly diagnosed unresectable stage III non-small cell lung cancer, with emphasis on survival, competing risks, safety, and…
- RTOG 0825Independent statistical analysis of RTOG 0825, a randomized phase 3 trial of temozolomide and radiation therapy with or without bevacizumab in patients with newly diagnosed glioblastoma.
- RxPONDERIndependent statistical analysis of the randomized phase 3 RxPONDER trial, including its invasive disease-free survival endpoint, Cox proportional-hazards analyses, menopausal-status interaction, post-hoc distant relapse-free survival results, safety, and statistical interpretation.
- S-TRACIndependent statistical analysis of the S-TRAC phase 3 trial of sunitinib versus placebo in patients at high risk of recurrent renal cell cancer, including disease-free survival, overall survival, trial design, Cox modeling,…
- SELECTComplete statistical analysis of SELECT (NCT01321554), the phase 3 randomized, double-blind, placebo-controlled trial of lenvatinib in 131I-refractory differentiated thyroid cancer, including progression-free survival, statistical methodology, safety, and interpretation.
- SEQUOIAIndependent statistical analysis of the phase 3 SEQUOIA trial comparing zanubrutinib with bendamustine plus rituximab in previously untreated chronic lymphocytic leukemia or small lymphocytic lymphoma, including its progression-free survival analysis and statistical…
- SHAPEIndependent statistical analysis of the SHAPE trial comparing radical versus simple hysterectomy with pelvic lymph node dissection for low-risk early stage cervical cancer, including its non-inferiority endpoint, time-to-event analyses, confidence intervals, and…